FLT3 internal tandem duplication mutations in adult acute myeloid leukaemia define a high-risk group

被引:246
作者
Abu-Duhier, FM [1 ]
Goodeve, AC [1 ]
Wilson, GA [1 ]
Gari, MA [1 ]
Peake, IR [1 ]
Rees, DC [1 ]
Vandenberghe, EA [1 ]
Winship, PR [1 ]
Reilly, JT [1 ]
机构
[1] Royal Hallamshire Hosp, Mol Haematol Unit, Div Med & Mol Genet, Sheffield S10 2JF, S Yorkshire, England
关键词
FLT3; oncogene; AML; prognosis; internal tandem duplication;
D O I
10.1046/j.1365-2141.2000.02317.x
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Genomic DNA from 106 cases of adult de novo acute myeloid leukaemia (AML) was screened by polymerase chain reaction (PCR) and gel electrophoresis for FLT3 internal tandem duplication (ITD) mutations within the juxtamembrane (JM) domain. FLT3 mutations were detected in 14 cases (13.2%) and occurred in FAB types M1 (4 out of 14 cases), M3 (1 out of 10 cases), M4 (5 out of 37 cases) and M5 (4 out of 11 cases). Sequence analysis of four cases with abnormal PCR electrophoretic patterns revealed in frame duplications in the region of exon 11 of between 27 and 111 base pairs. Three are predicted to result in the tandem duplication of adjacent amino acid residues and one to result in a tandem duplication plus insertion of a novel amino acid motif. Statistical analysis showed the FLT3 mutations to be a strong prognostic factor, with patients lacking the mutation surviving significantly longer from diagnosis (mean 29.1 months) than those with an ITD (mean 12.8 months; P = 0.0002). Thirteen of the 14 patients with FLT3 mutations died within 18 months of diagnosis. FLT3 mutations were of prognostic significance in good risk disease (P = 0.04), as well as in patients with standard risk disease (P = 0.0096). This study demonstrates that the FLT3 ITD mutation occurs in a significant percentage of adult AML cases and is an important adverse prognostic factor that appears independent of conventional karyotypic findings.
引用
收藏
页码:190 / 195
页数:6
相关论文
共 32 条
[1]   GENOMIC STRUCTURE OF THE DOWNSTREAM PART OF THE HUMAN FLT3 GENE - EXON/INTRON STRUCTURE CONSERVATION AMONG GENES ENCODING RECEPTOR TYROSINE KINASES (RTK) OF SUBCLASS-III [J].
AGNES, F ;
SHAMOON, B ;
DINA, C ;
ROSNET, O ;
BIRNBAUM, D ;
GALIBERT, F .
GENE, 1994, 145 (02) :283-288
[2]   c-kit activating mutations and mast cell proliferation in human leukemia [J].
Beghini, A ;
Larizza, L ;
Cairoli, R ;
Morra, E .
BLOOD, 1998, 92 (02) :701-702
[3]   PROPOSALS FOR CLASSIFICATION OF ACUTE LEUKEMIAS [J].
BENNETT, JM ;
CATOVSKY, D ;
DANIEL, MT ;
FLANDRIN, G ;
GALTON, DAG ;
GRALNICK, HR ;
SULTAN, C .
BRITISH JOURNAL OF HAEMATOLOGY, 1976, 33 (04) :451-&
[4]  
BIRG F, 1992, BLOOD, V80, P2584
[5]  
Drexler HG, 1996, LEUKEMIA, V10, P588
[6]  
Druker BJ, 1999, BLOOD, V94, p368A
[7]  
Fenski R, 2000, BRIT J HAEMATOL, V108, P322
[8]   IDENTIFICATION OF MUTATIONS IN THE CODING SEQUENCE OF THE PROTOONCOGENE C-KIT IN A HUMAN MAST-CELL LEUKEMIA-CELL LINE CAUSING LIGAND-INDEPENDENT ACTIVATION OF C-KIT PRODUCT [J].
FURITSU, T ;
TSUJIMURA, T ;
TONO, T ;
IKEDA, H ;
KITAYAMA, H ;
KOSHIMIZU, U ;
SUGAHARA, H ;
BUTTERFIELD, JH ;
ASHMAN, LK ;
KANAYAMA, Y ;
MATSUZAWA, Y ;
KITAMURA, Y ;
KANAKURA, Y .
JOURNAL OF CLINICAL INVESTIGATION, 1993, 92 (04) :1736-1744
[9]   c-kit proto-oncogene exon 8 in-frame deletion plus insertion mutations in acute myeloid leukaemia [J].
Gari, M ;
Goodeve, A ;
Wilson, G ;
Winship, P ;
Langabeer, S ;
Linch, D ;
Vandenberghe, E ;
Peake, I ;
Reilly, J .
BRITISH JOURNAL OF HAEMATOLOGY, 1999, 105 (04) :894-900
[10]   The importance of diagnostic cytogenetics on outcome in AML: Analysis of 1,612 patients entered into the MRC AML 10 trial [J].
Grimwade, D ;
Walker, H ;
Oliver, F ;
Wheatley, K ;
Harrison, C ;
Harrison, G ;
Rees, J ;
Hann, I ;
Stevens, R ;
Burnett, A ;
Goldstone, A .
BLOOD, 1998, 92 (07) :2322-2333